Literature DB >> 18417047

Novel therapies in hepatitis B and C.

Bart Takkenberg1, Joep de Bruijne, Christine Weegink, Peter Jansen, Hendrik Reesink.   

Abstract

Chronic hepatitis B and C affect approximately 500 million people in the world, with substantial disease burden including liver cirrhosis and hepatocellular carcinoma. For chronic hepatitis B, two treatment strategies are currently available, both with suboptimal response and significant side effects. Promising new drugs are approaching the stage of approval; however, these agents still need further development to control this disease. Based on the understanding of the hepatitis C virus life cycle, new treatment developments for chronic hepatitis C tend to succeed rapidly; therefore, it is only a matter of time before new therapies emerge. This review summarizes the most important new agents available for treatment of chronic hepatitis B and C.

Entities:  

Mesh：

Year:  2008        PMID： 18417047     DOI： 10.1007/s11894-008-0013-z

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  57 in total

Review 1.  The role of the hepatitis C virus glycoproteins in infection.

Authors:  M Flint; J A McKeating
Journal:  Rev Med Virol       Date:  2000 Mar-Apr       Impact factor: 6.989

Review 2.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

3.  The pathway of HCV IRES-mediated translation initiation.

Authors:  Geoff A Otto; Joseph D Puglisi
Journal:  Cell       Date:  2004-10-29       Impact factor: 41.582

4.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

5.  Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.

Authors:  Florian van Bömmel; Bernhard Zöllner; Christoph Sarrazin; Ulrich Spengler; Dietrich Hüppe; Bernd Möller; Heinz-Hubert Feucht; Bertram Wiedenmann; Thomas Berg
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

6.  Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

Authors:  Marion G Peters; Janet Andersen; Patrick Lynch; Tun Liu; Beverly Alston-Smith; Carol L Brosgart; Jeffrey M Jacobson; Victoria A Johnson; Richard B Pollard; James F Rooney; Kenneth E Sherman; Susan Swindells; Bruce Polsky
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

7.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.

Authors:  S W Schalm; J Heathcote; J Cianciara; G Farrell; M Sherman; B Willems; A Dhillon; A Moorat; J Barber; D F Gray
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

8.  A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.

Authors:  Seng Gee Lim; Tay Meng Ng; Nelson Kung; Zahary Krastev; Miroslava Volfova; Petr Husa; Samuel S Lee; Sing Chan; Mitchell L Shiffman; Mary Kay Washington; Amy Rigney; Jane Anderson; Elsa Mondou; Andrea Snow; Jeff Sorbel; Richard Guan; Franck Rousseau
Journal:  Arch Intern Med       Date:  2006-01-09

9.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

10.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Authors:  Marion G Peters; H w Hann Hw; Paul Martin; E Jenny Heathcote; P Buggisch; R Rubin; M Bourliere; K Kowdley; C Trepo; D f Gray Df; M Sullivan; K Kleber; R Ebrahimi; S Xiong; Carol L Brosgart
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682
View more
  2 in total

1.  Last stop before exit - hepatitis C assembly and release as antiviral drug targets.

Authors:  Birke Andrea Tews; Costin-Ioan Popescu; Jean Dubuisson
Journal:  Viruses       Date:  2010-08-24       Impact factor: 5.818

2.  Reasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study.

Authors:  Freke R Zuure; Titia Heijman; Anouk T Urbanus; Maria Prins; Gerjo Kok; Udi Davidovich
Journal:  BMC Public Health       Date:  2011-05-10       Impact factor: 3.295
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.